Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights from the Literature

What We're Reading

Article Recommendations from Our Deputy and Senior Editors

DOI:  Published April 2018
  • Article
  • Info & Metrics
  • PDF
Loading

Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1


Embedded Image

Targeting sugars (by Staff Sgt. Christopher Gross via Buckley Air Force Base)

PD-L1 glycosylation was found to be required for binding to PD-1 and immunosuppressive function in triple-negative breast cancer. In TNBC, EGF upregulates the enzyme B3GNT3 that catalyzes PD-L1 glycosylation. Binding of an Ab specific for glycosylated PD-L1 induces internalization and prevents inhibition by PD-1. Coupling this Ab to a cytotoxic drug kills tumor cells expressing glycosylated PD-L1 and bystanders. Targeting glycosylated PD-L1 on TNBC tumors is a potential strategy to enhance immune checkpoint therapy.

Li C-W, …, Hung M-C. Cancer Cell 2018 Feb 12;33:187–201.e10.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells


Embedded Image

Excluding T cells with TGFβ fences (by Wilson44691 via Wikimedia Commons)

Patients with urothelial cancer who respond to anti–PD-L1 treatment have higher neoantigen and CD8+ T cell levels, whereas nonresponders have more impenetrable tumors surrounded by fibroblasts with strong TGFβ signaling signatures. In a mouse model, addition of anti-TGFβ to anti–PD-L1 therapy enhances CD8+ T-cell infiltration into tumor centers, with concomitant antitumor immunity and tumor regression, highlighting the key role of TGFβ in shaping the tumor microenvironment.

Mariathasan S, …, Powles T. Nature 2018 Feb 14. doi:10.1038/nature25501.

Natural killer cells control tumor growth by sensing a growth factor


Embedded Image

The innate sensors (from B Vallentine et al. Cancer Immunol Res 2015)

PDGF-DD not only acts on tumor and stromal elements to promote tumor growth, but it also is a ligand for the activating NK-cell receptor NKp44. Many human cancers express PDGF-DD. Stimulating human ILC3, ILC1, and NK cells with it increases secretion of IFNγ and TNF and arrests tumor growth in vitro. Expression of NKp44 in mice correlates with more effective tumor control and enhances innate antitumor responses in combination with other immunotherapies.

Barrow AD, …, Colonna M. Cell 2018 Jan 25;172:534–48.e19.

NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting rancer immune control


Embedded Image

Recruiting the right skillset (from Library Company of Philadelphia via flickr)

Tumors secrete PGE2, preventing accumulation of conventional type 1 DCs (cDC1s) in tumors. cDC1s are attracted to tumors by NK-cell production of chemokines XCL1 and CCL5. However, PGE2 reduces chemokine production by NK cells and downregulates chemokine receptors on cDC1s, impairing migration. Strong NK-, chemokine-, and cDC1-gene signatures correlate with patient survival. These insights into the importance of NK–DC interplay suggest strategies to increase cDC1 infiltration for better cancer control.

Böttcher JP, …, Reis eSousa C. Cell 2018 Feb 8. doi: 10.1016/j.cell.2018.01.004.

Blocking PD-L1 on myeloid, not tumor, cells is key to developing antitumor immunity


Embedded Image

Myeloid cells in tumor digest (from Gros et al. Clin Cancer Res 2012)

The role of PD-L1 on tumor, stroma, and myeloid elements in the tumor microenvironment has remained uncertain. Two papers in The Journal of Clinical Investigation determined that the efficacy of PD-L1 blockade relies on the expression of PD-L1 on nontumor myeloid cells such as macrophages and dendritic cells. Expression of PD-L1 on tumor cells had little bearing on the success of blockade in reducing tumor burden in mouse models or clinical responses of patients.

Lin H, …, Zou W. J Clin Invest 2018 Feb 1;128:805–15.

Tang H, …, Fu Y-X. J Clin Invest 2018 Feb 1;128:580–8.

The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma


Embedded Image

Macrophage subsets in tumors (from Soncin et al. Fig. 3a)

Adult tissue-resident macrophages develop from the embryonic yolk sac progenitors and need no replenishment from hematopoietic sources. Intestinal tissue-resident macrophages are one of the exceptions, with rapid turnover forcing a constant reliance on circulating blood monocytes. CCR2-independent F4/80hi macrophages within colon tumors, however, are phenotypically similar to the neonatal macrophages, do not rely on circulating monocytes, are possibly maintained by tumor production of CSF1, and are supportive of tumor progression.

Soncin I, …, Ruedl C. Nat Commun 2018 Feb 8. doi:10.1038/s41467-018-02834-8.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Immunology Research: 6 (4)
April 2018
Volume 6, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
What We're Reading
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What We're Reading
Cancer Immunol Res April 1 2018 (6) (4) 371;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What We're Reading
Cancer Immunol Res April 1 2018 (6) (4) 371;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1
    • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
    • Natural killer cells control tumor growth by sensing a growth factor
    • NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting rancer immune control
    • Blocking PD-L1 on myeloid, not tumor, cells is key to developing antitumor immunity
    • The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • What We're Reading
  • What We're Reading
Show more Highlights from the Literature
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement